CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin

CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin

The Rejuvenation Startup Summit created by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. It is the world's largest gathering of Longevity startups in-person. The Summit brings together startups, members of the longevity venture capital/investor ecosystem, and researchers interested in founding or joining a startup.

Rejuvenation/Longevity biotech is a new, emerging field of medicine. It aims to prevent and reverse diseases of aging by addressing their common root cause, the aging process itself. Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production.


Dr. Alex Schueller, cellvie's CEO and co-founder, was one of the distinguished speakers invited from longevity biotech start-ups. Alex presented on the potential of mitochondria as a new treatment modality, not only for ischemia-reperfusion injury, but also for aging related degeneration. Loss of mitochondria function and mass has been reported in muscle degeneration and cellvie has been working to counter these developments with mitochondria transplantation.

Alex stated that in cellvie - "We believe mitochondria transplantation might help in mitigating and even reversing mitochondria damage across the aging space."

Alex's presentation at the Rejuvenation Startup Summit 2022 can be watched here:

About cellvie AG

Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. Schueller, McCully, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond since its founding cellvie has successfully expanded its team and operations close to Zürich.

Further information can be found at

Back to news
Line art Mitochondrium